Form 8-K - Current report:
SEC Accession No. 0001641172-25-015282
Filing Date
2025-06-16
Accepted
2025-06-16 17:00:28
Documents
15
Period of Report
2025-06-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 55588
2 EX-10.1 ex10-1.htm EX-10.1 154633
3 EX-99.1 ex99-1.htm EX-99.1 16590
4 GRAPHIC ex99-1_001.jpg GRAPHIC 16470
  Complete submission text file 0001641172-25-015282.txt   457359

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE fblg-20250616.xsd EX-101.SCH 3032
6 XBRL LABEL FILE fblg-20250616_lab.xml EX-101.LAB 34239
7 XBRL PRESENTATION FILE fblg-20250616_pre.xml EX-101.PRE 22370
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3810
Mailing Address 455 E. MEDICAL CENTER BLVD SUITE 300 SUITE 300 HOUSTON TX 77598
Business Address 455 E. MEDICAL CENTER BLVD SUITE 300 HOUSTON TX 77598 281-671-5150
FibroBiologics, Inc. (Filer) CIK: 0001958777 (see all company filings)

EIN.: 863329066 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41934 | Film No.: 251050933
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)